158 related articles for article (PubMed ID: 23817438)
21. Clinically different stages of Alzheimer's disease associated by amyloid deposition with [11C]-PIB PET imaging.
Hatashita S; Yamasaki H
J Alzheimers Dis; 2010; 21(3):995-1003. PubMed ID: 20693641
[TBL] [Abstract][Full Text] [Related]
22. Predicting biomarkers in intact older adults and those with amnestic Mild Cognitive Impairment, and mild Alzheimer's Disease using the Repeatable Battery for the Assessment of Neuropsychological Status.
Suhrie KR; Hammers DB; Porter SM; Dixon AM; King JB; Anderson JS; Duff K; Hoffman JM
J Clin Exp Neuropsychol; 2021 Nov; 43(9):861-878. PubMed ID: 35019815
[TBL] [Abstract][Full Text] [Related]
23. Differential Effects of the Interaction Between the Education and APOE ε4 Allele on Amyloid-beta Retention and Memory Performances in Cognitively Normal Older Adults and Alzheimer's Disease Patients.
Kang DW; Wang SM; Na HR; Lee CU; Baek IH; Lim HK
Curr Alzheimer Res; 2020; 17(11):1023-1032. PubMed ID: 33372875
[TBL] [Abstract][Full Text] [Related]
24. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
[TBL] [Abstract][Full Text] [Related]
25. Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease.
Bejanin A; Schonhaut DR; La Joie R; Kramer JH; Baker SL; Sosa N; Ayakta N; Cantwell A; Janabi M; Lauriola M; O'Neil JP; Gorno-Tempini ML; Miller ZA; Rosen HJ; Miller BL; Jagust WJ; Rabinovici GD
Brain; 2017 Dec; 140(12):3286-3300. PubMed ID: 29053874
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK
J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593
[TBL] [Abstract][Full Text] [Related]
27. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.
Vandenberghe R; Van Laere K; Ivanoiu A; Salmon E; Bastin C; Triau E; Hasselbalch S; Law I; Andersen A; Korner A; Minthon L; Garraux G; Nelissen N; Bormans G; Buckley C; Owenius R; Thurfjell L; Farrar G; Brooks DJ
Ann Neurol; 2010 Sep; 68(3):319-29. PubMed ID: 20687209
[TBL] [Abstract][Full Text] [Related]
28. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
Palmqvist S; Zetterberg H; Blennow K; Vestberg S; Andreasson U; Brooks DJ; Owenius R; Hägerström D; Wollmer P; Minthon L; Hansson O
JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
[TBL] [Abstract][Full Text] [Related]
29. An exploratory efficacy study of the amyloid imaging agent [(18)F]flutemetamol in Japanese Subjects.
Senda M; Yamamoto Y; Sasaki M; Yamane T; Brooks DJ; Farrar G; McParland B; Heurling K
Ann Nucl Med; 2015 Jun; 29(5):391-9. PubMed ID: 25874747
[TBL] [Abstract][Full Text] [Related]
30. Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
Jack CR; Lowe VJ; Weigand SD; Wiste HJ; Senjem ML; Knopman DS; Shiung MM; Gunter JL; Boeve BF; Kemp BJ; Weiner M; Petersen RC;
Brain; 2009 May; 132(Pt 5):1355-65. PubMed ID: 19339253
[TBL] [Abstract][Full Text] [Related]
31. Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease.
Voevodskaya O; Sundgren PC; Strandberg O; Zetterberg H; Minthon L; Blennow K; Wahlund LO; Westman E; Hansson O;
Neurology; 2016 May; 86(19):1754-61. PubMed ID: 27164711
[TBL] [Abstract][Full Text] [Related]
32. Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly.
Vemuri P; Lesnick TG; Przybelski SA; Knopman DS; Preboske GM; Kantarci K; Raman MR; Machulda MM; Mielke MM; Lowe VJ; Senjem ML; Gunter JL; Rocca WA; Roberts RO; Petersen RC; Jack CR
Brain; 2015 Mar; 138(Pt 3):761-71. PubMed ID: 25595145
[TBL] [Abstract][Full Text] [Related]
33. Relationship between atrophy and beta-amyloid deposition in Alzheimer disease.
Chételat G; Villemagne VL; Bourgeat P; Pike KE; Jones G; Ames D; Ellis KA; Szoeke C; Martins RN; O'Keefe GJ; Salvado O; Masters CL; Rowe CC;
Ann Neurol; 2010 Mar; 67(3):317-24. PubMed ID: 20373343
[TBL] [Abstract][Full Text] [Related]
34. Amyloid-β and cognition in aging and Alzheimer's disease: molecular and neurophysiological mechanisms.
Hampel H
J Alzheimers Dis; 2013; 33 Suppl 1():S79-86. PubMed ID: 22531423
[TBL] [Abstract][Full Text] [Related]
35. Assessment of perfusion deficit with early phases of [
Völter F; Beyer L; Eckenweber F; Scheifele M; Bui N; Patt M; Barthel H; Katzdobler S; Palleis C; Franzmeier N; Levin J; Perneczky R; Rauchmann BS; Sabri O; Hong J; Cumming P; Rominger A; Shi K; Bartenstein P; Brendel M
Eur J Nucl Med Mol Imaging; 2023 Apr; 50(5):1384-1394. PubMed ID: 36572740
[TBL] [Abstract][Full Text] [Related]
36. Repeatable battery for the assessment of neuropsychological status and its relationship to biomarkers of Alzheimer's disease.
Duff K; Suhrie KR; Hammers DB; Dixon AM; King JB; Koppelmans V; Hoffman JM
Clin Neuropsychol; 2023 Jan; 37(1):157-173. PubMed ID: 34713772
[TBL] [Abstract][Full Text] [Related]
37. Sensitivity of the Preclinical Alzheimer's Cognitive Composite (PACC), PACC5, and Repeatable Battery for Neuropsychological Status (RBANS) to Amyloid Status in Preclinical Alzheimer's Disease -Atabecestat Phase 2b/3 EARLY Clinical Trial.
Papp KV; Rofael H; Veroff AE; Donohue MC; Wang S; Randolph C; Grober E; Brashear HR; Novak G; Ernstrom K; Raman R; Aisen PS; Sperling R; Romano G; Henley D
J Prev Alzheimers Dis; 2022; 9(2):255-261. PubMed ID: 35542998
[TBL] [Abstract][Full Text] [Related]
38. Different aspects of Alzheimer's disease-related amyloid β-peptide pathology and their relationship to amyloid positron emission tomography imaging and dementia.
Thal DR; Ronisz A; Tousseyn T; Rijal Upadhaya A; Balakrishnan K; Vandenberghe R; Vandenbulcke M; von Arnim CAF; Otto M; Beach TG; Lilja J; Heurling K; Chakrabarty A; Ismail A; Buckley C; Smith APL; Kumar S; Farrar G; Walter J
Acta Neuropathol Commun; 2019 Nov; 7(1):178. PubMed ID: 31727169
[TBL] [Abstract][Full Text] [Related]
39. Regional brain amyloid-β accumulation associates with domain-specific cognitive performance in Parkinson disease without dementia.
Akhtar RS; Xie SX; Chen YJ; Rick J; Gross RG; Nasrallah IM; Van Deerlin VM; Trojanowski JQ; Chen-Plotkin AS; Hurtig HI; Siderowf AD; Dubroff JG; Weintraub D
PLoS One; 2017; 12(5):e0177924. PubMed ID: 28542444
[TBL] [Abstract][Full Text] [Related]
40. Appearance modeling of 11C PiB PET images: characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging.
Fripp J; Bourgeat P; Acosta O; Raniga P; Modat M; Pike KE; Jones G; O'Keefe G; Masters CL; Ames D; Ellis KA; Maruff P; Currie J; Villemagne VL; Rowe CC; Salvado O; Ourselin S
Neuroimage; 2008 Nov; 43(3):430-9. PubMed ID: 18789389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
